PharmaCyte Posts $5.1M Quarterly Loss, Flags Material Weaknesses and Nasdaq Delisting Risk
PMCB is trading near its 52-week low of $0.35 (12% above the low) on elevated volume (5.1× avg).
Summary
PharmaCyte Biotech reported a $5.08 million quarterly loss, disclosed material weaknesses in financial controls, and faces Nasdaq delisting unless it regains the $1.00 minimum bid price by November 30, 2026.
Key Events · Earnings and Guidance · PMCB
-
Quarterly Net Loss of $5.08 Million
Net loss attributable to common stockholders was $5.79 million ($0.54 per share) for the three months ended July 31, 2026, driven primarily by $8.7 million in fair-value losses on QCLS preferred stock and warrant investments.
-
Material Weaknesses in Internal Controls
Management disclosed two ongoing material weaknesses: insufficient segregation of duties of the CFO and insufficient management review controls, concluding disclosure controls were not effective as of July 31, 2026.
-
Nasdaq Delisting Risk
The company remains non-compliant with Nasdaq's $1.00 minimum bid price rule and has until November 30, 2026 to regain compliance. The board has authority to implement a reverse stock split at a ratio between 1-for-1.1 and 1-for-100.
-
Cash Runway of $17.7 Million
Cash and cash equivalents declined to $17.7 million from $18.6 million at April 30, 2026. Management expects this to fund operations for at least twelve months, but additional capital will be needed to complete a clinical trial.
Analysis · PMCB · Life Sciences
PharmaCyte's Q1 FY2027 10-Q reveals a $5.08 million net loss driven by $8.7 million in fair-value losses on its QCLS investments, while cash declined to $17.7 million. More critically, management disclosed two ongoing material weaknesses in internal controls and confirmed the company remains non-compliant with Nasdaq's $1.00 minimum bid price rule, with a November 30, 2026 deadline to regain compliance or face delisting. The board has authority to implement a reverse stock split to address the deficiency. These governance and listing risks compound the operational uncertainty from the FDA clinical hold on its pancreatic cancer program.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 35.7% of the 1179 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.44%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PMCB was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $0.35 to $1.51. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.